Dupixent is indicated for the approximately 300,000 adults in the US with inadequately controlled COPD and an eosinophilic phenotype
Ordspono is Regeneron’s first approved bispecific antibody and will provide an off-the-shelf option that can be administered in the out-patient setting, with hope for complete remission
This agreement paves the way for the introduction of YESAFILI into the Canadian market
Accelerating FDA submission and confirming potential to become first approved biologic for this serious disease
Bayer reported the highest market capitalization growth of 23.1% during Q1 2023
Viehbacher brings extensive international experience in large pharmaceutical and entrepreneurial biotech companies
Dupixent is the first and only biologic medicine approved to treat moderate-to-severe atopic dermatitis from infancy to adulthood
Aflibercept is the second biosimilar product that has entered the clinical trial phase after biosimilar Adalimumab
Dupixent peak sales ambition raised to more than €13 billion
Subscribe To Our Newsletter & Stay Updated
